Novartis Pharmaceuticals Corporation v. Handa Neuroscience, LLC et al
| Novartis Pharmaceuticals Corporation |
| Handa Pharmaceuticals, LLC, Handa Neuroscience, LLC, Handa Pharma, Inc. and Handa Pharmaceuticals, Inc. |
| 1:2021cv00645 |
| May 4, 2021 |
| US District Court for the District of Delaware |
| Leonard P Stark |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 1 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on March 1, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
SO ORDERED, re #13 STIPULATION and [Proposed] Order Governing Briefing Schedule for Defendants' Motion to Dismiss and/or Transfer filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 6/30/21. (ntl)
|
|
Filing 13
STIPULATION and [Proposed] Order Governing Briefing Schedule for Defendants' Motion to Dismiss and/or Transfer by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 12
REDACTED VERSION of #10 Opening Brief in Support,, by Handa Neuroscience, LLC, Handa Pharma, Inc., Handa Pharmaceuticals, Inc., Handa Pharmaceuticals, LLC. (Attachments: #1 Exhibit 1-2)(Bilson, David)
|
|
Filing 11
Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Handa Neuroscience, LLC for Handa Neuroscience, LLC, Handa Pharmaceuticals, LLC; Corporate Parent Handa Pharmaceuticals, Inc. for Handa Pharma, Inc. filed by Handa Neuroscience, LLC, Handa Pharma, Inc., Handa Pharmaceuticals, Inc., Handa Pharmaceuticals, LLC. (Phillips, John)
|
|
Filing 10
[SEALED] OPENING BRIEF in Support re #9 MOTION to Dismiss Based upon Rule 12(b)(6) of the Federal Rule of Civil Procedure, Rule 12(b)(3) of the Federal Rule of Civil Procedure and Northern District of California under 28 U.S.C. 1404(a) and 1406(a) filed by Handa Neuroscience, LLC, Handa Pharma, Inc., Handa Pharmaceuticals, Inc., Handa Pharmaceuticals, LLC.Answering Brief/Response due date per Local Rules is 7/6/2021. (Attachments: #1 Exhibit 1-2)(Phillips, John)
|
|
Filing 9
MOTION to Dismiss Based upon Rule 12(b)(6) of the Federal Rule of Civil Procedure, Rule 12(b)(3) of the Federal Rule of Civil Procedure and Northern District of California under 28 U.S.C. 1404(a) and 1406(a) - filed by Handa Neuroscience, LLC, Handa Pharma, Inc., Handa Pharmaceuticals, Inc., Handa Pharmaceuticals, LLC. (Attachments: #1 Text of Proposed Order)(Phillips, John)
|
|
Filing 8
MOTION for Pro Hac Vice Appearance of Attorney Jane M. Love, Ph.D., Robert W. Trenchard, Andrew P. Blythe, and Christine L. Ranney - filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certifications for Jane M. Love, Ph.D., Robert W. Trenchard, Andrew P. Blythe, and Christine L. Ranney)(Silver, Daniel)
|
|
SO ORDERED, re #8 MOTION for Pro Hac Vice Appearance of Attorney Jane M. Love, Ph.D., Robert W. Trenchard, Andrew P. Blythe, and Christine L. Ranney filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 5/27/21. (ntl)
|
|
SO ORDERED, re #7 STIPULATION and [Proposed] Order Governing Acceptance of Service of Process and Response Time to Complaint filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 5/21/21. (ntl)
|
|
Filing 7
STIPULATION and [Proposed] Order Governing Acceptance of Service of Process and Response Time to Complaint by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
|
|
Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (rjb)
|
|
Filing 6
Summonses Issued (please complete the top portion of the form and print out for use/service). (apk)
|
|
Filing 5
Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (apk)
|
|
Filing 4
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,187,405 ;10,543,179. (apk)
|
|
Filing 3
Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 04/13/2021. Date of Expiration of Patent: SEE ATTACHED.Thirty Month Stay Deadline: 10/13/2023. (apk)
|
|
Filing 2
Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (apk)
|
|
Filing 1
COMPLAINT filed against Handa Neuroscience, LLC, Handa Pharma, Inc., Handa Pharmaceuticals, Inc., Handa Pharmaceuticals, LLC - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3608022.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-C, #2 Civil Cover Sheet)(apk)
|
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
